7/107 sources · 6 publishersUpdated Oct 8, 19:33 UTC
Johnson & Johnson reports two-year ICOTYDE psoriasis trial results
Johnson & Johnson released two-year Phase 3 ICONIC-TOTAL results for ICOTYDE in plaque psoriasis affecting high-impact body sites. By Week 112, 70% of treated participants had an Investigator's Global Assessment score of 0 or 1, while complete clearance was reported in 60% of scalp cases, 89% of genital cases and 63% of hand or foot cases. The company said no new safety signals emerged during the study period.
Why it matters
The update adds long-term Phase 3 evidence for ICOTYDE in psoriasis areas that can be difficult to treat. Johnson & Johnson said the safety findings remained in line with the drug's established profile.
Key facts
- 1Johnson & Johnson presented the Phase 3 ICONIC-TOTAL findings at the EADV Congress 2026. prnewswire.com
- 2The share of ICOTYDE-treated patients rated clear or almost clear rose from 57% at Week 16 to 70% at Week 112. prnewswire.com
- 3At Week 112, 60% of participants with scalp psoriasis recorded a scalp-specific assessment score of 0. prnewswire.com
- 4At Week 112, 89% of participants with genital psoriasis recorded a genital assessment score of 0. prnewswire.com
- 5Johnson & Johnson reported no new safety signals through Week 112. prnewswire.com
Open questions
- The materials do not provide participant counts, statistical significance measures, or full comparator results for the Week 112 outcomes.
Summary written by AlphAI from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.